Accel Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
SLAM
Accel Wealth Management's BMY Position: Q2 2026 in Review
Accel Wealth Management increased its Bristol-Myers Squibb (BMY) stake by 0.31% in Q2 2026, buying an estimated $632 and bringing the position to 3,580 shares worth $206K. The position accounts for 0.05% of the portfolio, ranked #287.
Accel Wealth Management first reported a position in BMY in Q4 2020 and has held it in 19 quarters since. The position peaked at $281K in Q1 2025. 1,031 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Accel Wealth Management held 3,580 shares of Bristol-Myers Squibb worth $206K as of Q2 2026.
- Accel Wealth Management bought 11 Bristol-Myers Squibb shares in Q2 2026, an estimated $632.
- Bristol-Myers Squibb made up 0.05% of Accel Wealth Management's portfolio in Q2 2026, its #287 holding.
- Accel Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 19 quarters since.
- Accel Wealth Management's Bristol-Myers Squibb position peaked at $281K in Q1 2025.
- 1,031 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Accel Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.